医药品产业的授权契约 (2020-2025年)

本报告提供了2020年至2025年製药业授权协议的详细资讯。它提供了各方宣布的许可协议的付款条款，并提供了有关付款条款和其他交易条款的宝贵见解。

主要优势

本报告提供读者以下主要优势：

• 了解2020年及以后的合约趋势
• 浏览许可协议
• 基准分析：了解交易的市场价值
• 财务条款：有关预付款、里程碑付款和特许权使用费的信息
• 合约目录：依公司（A-Z）、治疗领域、技术类型分类
• 按价值划分的主要合约
• 识别最活跃的承包商
• 识别每笔交易的资产和条款
• 存取合约文件：深入了解合约结构
• 尽职调查：评估您的合约条款与合作伙伴的一致性
• 节省数百小时的研究时间

调查范围

• 生物製药产业的授权协议趋势
• 许可协议结构概述
• 製药和生物技术领域许可协议记录目录
• 按价值划分的主要授权协议
• 最活跃的许可公司
• 主要的许可合作伙伴资源

可利用契约的清单:

• 企业 (A～Z)
• 契约总额
• 治疗领域
• 技术类型

目录

摘要整理

第1章 简介

第2章 授权交易趋势

• 授权契约定义
• 2020年以后的授权契约趋势
  • 2020～2025年的授权契约:各年度
  • 2020～2025年的授权契约:各开发阶段
  • 2020～2025年的授权契约:各业界
  • 2020～2025年的授权契约:各治疗领域
  • 2020～2025年的授权契约:各技术类型
  • 2020～2025年的授权契约:最活跃的各企业
• 原因建立许可合作关係
• 许可协议的未来

第3章 授权契约结构:概要

• 授权契约结构

第4章 主要授权契约

• 首位授权契约:各金额

第5章 最活跃的授权契约企业:前25家

• 最活跃的授权契约企业:前25家

第6章 含契约名录的授权契约

• 包含从2020年到2025年契约的授权契约
• 契约名录
• 契约名录- 各企业授权契约 (A-Z)
• 契约名录- 各治疗领域的授权契约
• 契约名录- 各技术类型的授权契约
• 关于Biopharma Research
• 目前联盟
• 目前契约
• Current Partnering的最近报告标题

Licensing Deals in Pharmaceuticals provides a detailed understanding and analysis of how and why companies enter licensing deals.

Fully revised and updated, the report provides details of licensing deals from 2020 to 2025.

The report provides access to licensing deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of licensing deals announced since 2020 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of licensing dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in licensing as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of licensing deals.

Chapter 4 provides a review of the leading licensing deals since 2020. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive listing of the top 25 most active licensing dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 6 provides a comprehensive and detailed review of licensing deals organized by company A-Z, therapy, technology and industry type signed and announced since 2020 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the licensing deal.

The deal directory includes a comprehensive listing of all licensing deals announced since 2020. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends and activities in licensing dealmaking since 2020.

In conclusion, this report provides everything a prospective dealmaker needs to know about licensing alliances.

Key benefits

Licensing Deals in Pharmaceuticals provides the reader with the following key benefits:

• Understand deal trends since 2020
• Browse licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Licensing Deals in Pharmaceuticals is intended to provide the reader with an in-depth understanding of the licensing trends and structure of deals entered into by leading biopharma companies worldwide.

Licensing Deals in Pharmaceuticals includes:

• Trends in licensing dealmaking in the biopharma industry
• Overview of licensing deal structure
• Directory of licensing deal records covering pharmaceutical and biotechnology
• The leading licensing deals by value
• Most active licensing dealmakers
• The leading licensing partnering resources

In Licensing Deals in Pharmaceuticals, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Licensing Deals in Pharmaceuticals provides comprehensive access to available records for licensing deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the rights granted or optioned?
• What rights are granted by the agreement?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are intellectual property rights handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in licensing dealmaking

• 2.1. Introduction
• 2.2. Definition of licensing deal
• 2.3. Trends in licensing deals since 2020
  • 2.3.1. Licensing dealmaking by year, 2020-2025
  • 2.3.2. Licensing dealmaking by phase of development, 2020-2025
  • 2.3.3. Licensing dealmaking by industry sector, 2020-2025
  • 2.3.4. Licensing dealmaking by therapy area, 2020-2025
  • 2.3.5. Licensing dealmaking by technology type, 2020-2025
  • 2.3.6. Licensing dealmaking by most active company, 2020-2025
• 2.4. Reasons for entering into licensing partnering deals
• 2.5. The future of licensing deals

Chapter 3 - Overview of licensing deal structure

• 3.1. Introduction
• 3.2. Licensing agreement structure

Chapter 4 - Leading licensing deals

• 4.1. Introduction
• 4.2. Top licensing deals by value

Chapter 5 - Top 25 most active licensing dealmakers

• 5.1. Introduction
• 5.2. Top 25 most active licensing dealmakers

Chapter 6 - Licensing deals including contracts directory

• 6.1. Introduction
• 6.2. Licensing deals with contracts 2020-2025
• Deal directory
• Deal directory - licensing dealmaking by companies A-Z
• Deal directory - licensing dealmaking by therapy area
• Deal directory - licensing dealmaking by technology type
• About Biopharma Research
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Definition of licensing
• Figure 2: Trends in licensing deal announcements, 2020-2025
• Figure 3: Licensing deals signed at each phase of development, 2020-2025
• Figure 4: Licensing deals by industry sector, 2020-2025
• Figure 5: Licensing deals by therapy area, 2020-2025
• Figure 6: Licensing deals by technology type, 2020-2025
• Figure 7: Top 25 most active licensing dealmakers, 2020-2025
• Figure 8: Top licensing deals by value, 2020-2025
• Figure 9: Most active licensing dealmakers, 2020-2025